NCT02758392View on ClinicalTrials.gov

A Study to Evaluate Safety and Tolerability of JNJ-61178104 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

January 31, 2017

Study Completion Date

January 31, 2017

Conditions
Healthy
Interventions
DRUG

JNJ-61178104 Intravenous

Participants will receive JNJ-61178104 Intravenously on Day 1.

DRUG

JNJ-61178104 Subcutaneous

Participants will receive JNJ-61178104 Subcutaneously on Day 1.

DRUG

Placebo

Participants will receive placebo on Day 1.

Trial Locations (1)

Unknown

Merksem

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT02758392 - A Study to Evaluate Safety and Tolerability of JNJ-61178104 in Healthy Participants | Biotech Hunter | Biotech Hunter